Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma
复制标题
DOI：
10.1016/j.cllc.2016.03.009
复制
发表时间：
2016-09-01
影响因子：
3.6
通讯作者：
Sica, Gabriel L.
中科院分区：
文献类型：
--
作者：
Behera, Madhusmita;Owonikoko, Taofeek K.;Sica, Gabriel L.
我们对已发表的数据进行了系统分析，以评估肺腺癌的原位腺癌和微浸润腺癌亚类之间的预后差异。在微浸润腺癌和原位肺腺癌患者的生存率方面未发现显著差异。我们的研究结果对这些肿瘤类型进行亚分期的必要性提出了质疑。
背景：肺腺癌几乎占非小细胞肺癌的60%。根据2011年国际肺癌研究协会（IASLC）、美国胸科学会（ATS）和欧洲呼吸学会（ERS）的分类以及2015年世界卫生组织肺部肿瘤分类，贴壁为主型腺癌……
We conducted a systematic analysis of published data to evaluate the prognostic differences between the adenocarcinoma in situ and minimally invasive adenocarcinoma subcategories of lung adenocarcinoma. No significant differences were found in the survival rates between patients with minimally invasive adenocarcinoma and adenocarcinoma in situ lung adenocarcinoma. Our results raise questions regarding the need for the substaging of these tumor types.Background: Lung adenocarcinoma accounts for almost 60% of non-small-cell lung cancer. According to the 2011 International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) classification and 2015 World Health Organization classification of tumors of the lung, lepidic-predominant adenocarcinomas